Does a plasma level of chlorpromazine help?
Forty-eight newly admitted schizophrenic patients were treated with a fixed, conservative (6.6 mg/kg) dose of chlorpromazine (CPZ) for 28 days. CPZ plasma levels were measured by a gas chromatography mass spectrometry method (GCMS) using 2H6-chlorpromazine as an internal standard. At the end of the fixed-dose period, "responders" had the same plasma levels as "non-responders", suggesting that lack of response is primarily a matter of the illness' sensitivity to CPZ, not to a plasma level below some therapeutic window. After the fixed-dose period, the dosage of CPZ was increased in the "non-responders" by physician's choice. Improvement occurred over a wide range of 10-225 picomoles (3-72 ng)/ml. Above 300 picomoles (95 ng/ml) 4 inaccessible patients eventually became much worse, suggesting psychotoxicity. It is in the inaccessible patient whose illness is only minimally, or not at all, sensitive to CPZ that a plasma level might be especially useful. Interpretation of plasma levels is complicated by the speed of response: some initial non-responders improved by the 56th day of treatment on very conservative plasma levels.
D010054:Brief Psychiatric Rating Scale; D002746:Chlorpromazine / Q000008:administration & dosage / Q000097:blood*; D002849:Chromatography, Gas; D006801:Humans; D013058:Mass Spectrometry; D010043:Outcome and Process Assessment, Health Care; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*
D002746:Chlorpromazine